| Date | Form | Description | Docs | XBRL | Pages |
| 06/18/96 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
2 | |
| 06/14/96 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
4 | |
| 06/13/96 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
14 | |
| 04/24/96 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
4 | |
| 04/22/96 | 8-K | Current report filing |
|
4 | |
| 03/14/96 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
12 | |
| 01/29/96 | 10-K405 | Annual report [Sections 13 and 15(d), S-K Item 405] |
|
44 | |
| 09/12/95 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
16 | |
| 09/06/95 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
15 | |
| 09/06/95 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
2 |
Latest News & Events
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Read More...Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Read More...Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Read More...